PerkinElmer Acquires Proteomics Labeling Technology of Agilix Corporation; Acquisition Solidifies Leadership Position in Quantitative Proteomics.

BOSTON -- PerkinElmer, Inc. (NYSE: PKI), a global technology leader in Health Sciences and Photonics, today announced the acquisition of Agilix Corporation's proprietary proteomics technology. Agilix has developed a powerful labeling technology using isobaric mass tags that allows for the simultaneous quantification of molecules, such as proteins, from multiple samples. This technology now brings quantitative proteomics to PerkinElmer customers in drug discovery and proteomics research. Furthermore, it provides a powerful technique for enhancing the utility of mass spectrometry, a preferred method for proteomic analysis. Terms of the deal were not disclosed.

This innovative technology is a superior approach for determining the relative expression level of individual proteins from multiple samples with a high degree of precision. Samples are tagged and mixed early in sample processing workflow, enabling simultaneous sample analysis and eliminating errors caused by spurious variation seen in currently practiced serial processing workflows. This mass spectrometry-based approach allows unambiguous detection and identification of proteins without the use of analyte-specific reagents.

"The Agilix multiplex protein labeling technology represents a breakthrough in quantitative proteomics. This leading-edge technology reduces the process workflow in proteomics analysis, and enables more accurate studies in protein expression kinetics and pharmacodynamics," said Neil Cook, chief scientific officer, PerkinElmer Life and Analytical Sciences.

This technology was first pioneered by Rockefeller University Professor Brian Chait, who said, "the ability to determine changes in the levels of proteins as a function of time and circumstance is vital to gaining an understanding of complex biological systems."

"PerkinElmer will use the intellectual property acquired from Agilix to develop a number of new technologies that will bring quantitative proteomics to a wider range of customers in drug discovery," added Robert F. Friel, president, PerkinElmer Life and Analytical Sciences.

The acquisition of this isobaric mass tag technology further strengthens PerkinElmer's position as the partner-of-choice to proteomic laboratories and researchers, and complements the launch of PerkinElmer's BioXPRESSIONS(TM) platform and the recent announcement of a licensing agreement for the multiplexing bead-based technology from Luminex(R).

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) economic and geopolitical forces that may limit any continued or expected economic or end market strengthening or recoveries; (2) risks related to our failure to introduce new products in a timely manner; (3) our ability to comply with financial covenants contained in our credit agreements and our debt instruments; (4) a delay in resolution of the Company's tax audits and an adverse determination with respect to the Company's tax audits by the Internal Revenue Service or other taxing authorities; (5) cyclical downturns continuing to affect several of the industries into which we sell our products; (6) our ability to adjust our operations to address unexpected changes; (7) our ability to execute acquisitions and license technologies and successfully integrate acquired businesses and licensed technologies into our existing business; (8) the loss of any of our licenses that may require us to stop selling products or lose competitive advantage; (9) competition; (10) regulatory compliance; (11) regulatory changes; (12) our failure to obtain and enforce intellectual property protection; (13) our defense of third party claims of patent infringement and our ability to realize the full value of our intangible assets; (14) other factors which we describe under the caption "Forward-Looking Information and Factors Affecting Future Performance" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information

Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.5 billion in 2005, has 8,000 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

Agilix Corporation is a research and development company engaged in creating protein labeling tools for quantitative analysis. The company is located in Woodbridge, Connecticut.